GLP-1 Agonist vs Dual Incretin — Metabolic Deal Terms Comparison
Market Analysis
In metabolic, GLP-1 Agonist and Dual Incretin represent two of the most actively transacted modalities. At Phase 2, GLP-1 Agonist deals carry a median total deal value of $4.5B with $935M upfront, compared to $5.9B total value and $1.2B upfront for Dual Incretin. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. GLP-1 Agonist development milestones average $647M versus $839M for Dual Incretin. Commercial milestones are $2.2B for GLP-1 Agonist and $2.8B for Dual Incretin. Royalty rates range from 16.1%-29.5% for GLP-1 Agonist and 17.4%-30% for Dual Incretin.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do GLP-1 Agonist and Dual Incretin deal terms compare in metabolic?
Which modality commands higher royalty rates: GLP-1 Agonist or Dual Incretin?
How do milestone structures differ between GLP-1 Agonist and Dual Incretin?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.